Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
Giles Dixon,Samuel Hague,Sarah Mulholland,Huzaifa Adamali,Aye Myat Noe Khin,Hannah Thould,Roisin Connon,Paul Minnis,Eoin Murtagh,Fasihul Khan,Sameen Toor,Alexandra Lawrence,Marium Naqvi,Alex West,Robina K Coker,Katie Ward,Leda Yazbeck,Simon Hart,Theresa Garfoot,Kate Newman,Pilar Rivera-Ortega,Lachlan Stranks,Paul Beirne,Jessica Bradley,Catherine Rowan,Sarah Agnew,Mahin Ahmad,Lisa G Spencer,Joshua Aigbirior,Ahmed Fahim,Andrew M Wilson,Elizabeth Butcher,Sy Giin Chong,Gauri Saini,Sabrina Zulfikar,Felix Chua,Peter M George,Maria Kokosi,Vasileios Kouranos,Philip Molyneaux,Elisabetta Renzoni,Benedetta Vitri,Athol U Wells,Lisa M Nicol,Stephen Bianchi,Raman Kular,HuaJian Liu,Alexander John,Sarah Barth,Melissa Wickremasinghe,Ian A Forrest,Ian Grimes,A John Simpson,Sophie V Fletcher,Mark G Jones,Emma Kinsella,Jennifer Naftel,Nicola Wood,Jodie Chalmers,Anjali Crawshaw,Louise E Crowley,Davinder Dosanjh,Christopher C Huntley,Gareth I Walters,Timothy Gatheral,Catherine Plum,Shiva Bikmalla,Raja Muthusami,Helen Stone,Jonathan C L Rodrigues,Krasimira Tsaneva-Atanasova,Chris J Scotton,Michael A Gibbons,Shaney L Barratt
DOI: https://doi.org/10.1183/23120541.00529-2023
2024-01-15
Abstract:Background: Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service in Scotland in June 2021 and in England, Wales and Northern Ireland in November 2021. To date, there has been no national evaluation of the use of nintedanib for PF-ILD in a real-world setting. Methods: 26 UK centres were invited to take part in a national service evaluation between 17 November 2021 and 30 September 2022. Summary data regarding underlying diagnosis, pulmonary function tests, diagnostic criteria, radiological appearance, concurrent immunosuppressive therapy and drug tolerability were collected via electronic survey. Results: 24 UK prescribing centres responded to the service evaluation invitation. Between 17 November 2021 and 30 September 2022, 1120 patients received a multidisciplinary team recommendation to commence nintedanib for PF-ILD. The most common underlying diagnoses were hypersensitivity pneumonitis (298 out of 1120, 26.6%), connective tissue disease associated ILD (197 out of 1120, 17.6%), rheumatoid arthritis associated ILD (180 out of 1120, 16.0%), idiopathic nonspecific interstitial pneumonia (125 out of 1120, 11.1%) and unclassifiable ILD (100 out of 1120, 8.9%). Of these, 54.4% (609 out of 1120) were receiving concomitant corticosteroids, 355 (31.7%) out of 1120 were receiving concomitant mycophenolate mofetil and 340 (30.3%) out of 1120 were receiving another immunosuppressive/modulatory therapy. Radiological progression of ILD combined with worsening respiratory symptoms was the most common reason for the diagnosis of PF-ILD. Conclusion: We have demonstrated the use of nintedanib for the treatment of PF-ILD across a broad range of underlying conditions. Nintedanib is frequently co-prescribed alongside immunosuppressive and immunomodulatory therapy. The use of nintedanib for the treatment of PF-ILD has demonstrated acceptable tolerability in a real-world setting.